Effects of early plasmin digests of fibrinogen on isometric tension development in isolated rings of rat pulmonary artery

Thrombosis Research

Volumn 81, Issue 2, 1996, Pages 231-239

  Boutcher, Paul A ^a   Gaffney, Patrick J ^b   Raut, Sanjeev ^b   O'Regan, Ronan G ^a   McLoughlin, Paul ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Rat fibrinogen peptides; Rat pulmonary artery; Vasoactive effects

Indexed keywords

FIBRINOGEN; PHENYLEPHRINE; PLASMIN;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; LUNG ARTERY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT;

EID: 0029875975     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/0049-3848(95)00240-5     Document Type: Article

References (17)

1. GARBEDIAN H.D., GOLD H.K., LEINBACH R.C., YASUDA T, JOHNS J.A. and COLLEN D. Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of recombinant human tissue-type plasminogen activator for coronary-thrombosis. Am J Cardiol 58, 673-679, 1986.
2. GAFFNEY, P.J. First-and second-generation thrombolytic agents: mechanistic and clinical compatibility. In: Coronary thrombosis: intracardiac thrombosis. P. Pérez-Goméz, C.R.M. Prentice and J. Meyer (eds.), pp. 101-113, Raven Press Ltd, New York (1994).
3. GAFFNEY, P.J. Tissue plasminogen activator for thrombolytic therapy: expectation versus reality. J Royal Soc Med 85, 692-698, 1992.
4. KERN D.F., SALDEEN K., SALDEEN T. and MALIK A.B. Pulmonary vascular effects of a fibrin(ogen)-derived vasoactive peptide. Thromb Res 42, 783-788, 1986.
5. MEHTA J., WARGOVICH T., NICHOLS W.W., SALDEEN K., WALLIN R. and SALDEEN T. Peptide 6A, a fibrin(ogen) degradation product, increases coronary blood flow. Am J Physiol 249, H457-H462, 1985.
6. NICHOLS W.W., MEHTA J., WARGOVICH T., SALDEEN K., WALLIN R. and SALDEEN T. Fibrin(ogen)-derived peptide Bβ 30-43 increases coronary blood flow in the anesthetized dog. Thromb Res 38, 223-229, 1985.
7. SALDEEN K., NICHOLS W., LAWSON D., ANDERSSON R., SALDEEN T. and MEHTA J. Fibrin(ogen) degradation product peptide 6A increases femoral artery blood flow in dogs. Acta Physiol Scand 142, 339-344, 1991.
8. ANDERSSON R.G.G., SALDEEN K. and SALDEEN T. A fibrin(ogen) derived pentapeptide induces vasodilation, prostacyclin release and an increase in cyclic AMP. Thromb Res 30, 213-218, 1983.
9. HAYNES J.B., HYERS T.M., GICLAS P.C., FRANKS J.J. and PETTY T.L. Elevated fibrin(ogen) degradation products in the adult respiratory distress syndrome. Am Rev Respir Dis 122, 841-847, 1980.
10. LUTERMAN A., MANWARING D. and CURRERI P.W. The role of fibrinogen degradation products in the pathogenesis of the respiratory distress syndrome. Surgery 82, 703-709, 1977.
11. TAKAHASHI H., TATEWAKI W., WADA K., NIWANO H. and SHIBATA A. Fibrinolysis and fibrinogenolysis in disseminated intravascular coagulation. Thromb Haemostas 63, 340-344, 1990.
12. GAFFNEY P.J. and LONGSTAFF C. Fibrinolysis. In: Haemostasis and Thrombosis A.L. Bloom, C.D. Forbes, D.P. Thomas, E.G.D. Tuddenham (eds), pp. 549-573, Churchill Livingstone, London (1994).
13. GAFFNEY P.J., CHESTERMAN C.N. and ALLINGTON M.J. Plasma fibrinogen and its fragments during streptokinase treatment. Brit J Haematol 26, 285-293, 1974.
14. GAFFNEY P.J., LANE D.A. and BRASHER M. Soluble high molecular weight E fragments in the plasmin-induced degradation products of crosslinked fibrin. Clin Sci Mol Med. 49, 149-156, 1975.
15. MOSESSON M. W. The fibrinolytic pathway of fibrinogen catabolism. Thrombosis Research 2, 185-200 1973.
16. BENNIE R.E., PACKER C.S., POWELL D.R., JIN N. and RHOADES R.A. Biphasic contractile response of pulmonary artery to hypoxia. Am J Physiol 261, L156-L163, 1991.
17. SALDEEN T. Vasoactive peptides derived from degradation of fibrinogen and fibrin. Ann NY Acad Sci 408, 424-437 June 27, 1983.